1. Home
  2. ACIU vs ELA Comparison

ACIU vs ELA Comparison

Compare ACIU & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • ELA
  • Stock Information
  • Founded
  • ACIU 2003
  • ELA 1965
  • Country
  • ACIU Switzerland
  • ELA United States
  • Employees
  • ACIU N/A
  • ELA N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • ELA Consumer Specialties
  • Sector
  • ACIU Health Care
  • ELA Consumer Discretionary
  • Exchange
  • ACIU Nasdaq
  • ELA Nasdaq
  • Market Cap
  • ACIU 213.3M
  • ELA 198.1M
  • IPO Year
  • ACIU 2016
  • ELA N/A
  • Fundamental
  • Price
  • ACIU $2.48
  • ELA $7.42
  • Analyst Decision
  • ACIU Strong Buy
  • ELA Strong Buy
  • Analyst Count
  • ACIU 2
  • ELA 1
  • Target Price
  • ACIU $10.00
  • ELA $9.00
  • AVG Volume (30 Days)
  • ACIU 132.0K
  • ELA 56.5K
  • Earning Date
  • ACIU 11-04-2025
  • ELA 11-04-2025
  • Dividend Yield
  • ACIU N/A
  • ELA N/A
  • EPS Growth
  • ACIU N/A
  • ELA 34.09
  • EPS
  • ACIU N/A
  • ELA 0.33
  • Revenue
  • ACIU $36,362,036.00
  • ELA $198,354,109.00
  • Revenue This Year
  • ACIU N/A
  • ELA $14.43
  • Revenue Next Year
  • ACIU $1,022.98
  • ELA $2.60
  • P/E Ratio
  • ACIU N/A
  • ELA $21.50
  • Revenue Growth
  • ACIU 86.71
  • ELA 24.35
  • 52 Week Low
  • ACIU $1.43
  • ELA $5.10
  • 52 Week High
  • ACIU $3.98
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 64.11
  • ELA 58.19
  • Support Level
  • ACIU $2.12
  • ELA $6.95
  • Resistance Level
  • ACIU $2.35
  • ELA $7.76
  • Average True Range (ATR)
  • ACIU 0.13
  • ELA 0.32
  • MACD
  • ACIU 0.04
  • ELA -0.07
  • Stochastic Oscillator
  • ACIU 95.74
  • ELA 56.63

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: